Proteasome inhibitorFDA-approvedSecond-line
Carfilzomib
How it works
Blocks the proteasome, a complex involved in protein degradation, which is overactive in multiple myeloma cells, leading to cell death.
Cancer types
Leukemia— Multiple myeloma
Efficacy
In clinical trials, around 70% of multiple myeloma patients achieved an objective response, with a median progression-free survival of approximately 9 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.